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Genetic and clinical 
characterization of Pakistani 
families with Bardet-Biedl 
syndrome extends the genetic and 
phenotypic spectrum
Maleeha Maria1,2,*, Ideke J. C. Lamers2,3,*, Miriam Schmidts2,3,4,5, Muhammad Ajmal1, 
Sulman Jaffar6, Ehsan Ullah7,8, Bilal Mustafa1, Shakeel Ahmad1, Katia Nazmutdinova4, 
Bethan Hoskins9, Erwin van Wijk10,11, Linda Koster-Kamphuis12, Muhammad Imran Khan2, 
Phil L. Beales4,13, Frans P. M. Cremers2,11, Ronald Roepman2,3, Maleeha Azam1,†, 
Heleen H. Arts2,3,14,† & Raheel Qamar1,15,16,†
Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder that is both genetically and clinically 
heterogeneous. To date 19 genes have been associated with BBS, which encode proteins active at the 
primary cilium, an antenna-like organelle that acts as the cell’s signaling hub. In the current study, a 
combination of mutation screening, targeted sequencing of ciliopathy genes associated with BBS, and 
whole-exome sequencing was used for the genetic characterization of five families including four with 
classic BBS symptoms and one BBS-like syndrome. This resulted in the identification of novel mutations 
in BBS genes ARL6 and BBS5, and recurrent mutations in BBS9 and CEP164. In the case of CEP164, this 
is the first report of two siblings with a BBS-like syndrome with mutations in this gene. Mutations in this 
gene were previously associated with nephronophthisis 15, thus the current results expand the CEP164-
associated phenotypic spectrum. The clinical and genetic spectrum of BBS and BBS-like phenotypes is not 
fully defined in Pakistan. Therefore, genetic studies are needed to gain insights into genotype-phenotype 
correlations, which will in turn improve the clinician’s ability to make an early and accurate diagnosis, and 
facilitate genetic counseling, leading to directly benefiting families with affected individuals.
Bardet-Biedl syndrome (BBS) is a complex, heterogeneous, autosomal recessively inherited disorder. The 19 
causative genes that have been identified thus far1 encode proteins that function at different sites of the primary 
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cilium, a non-motile oblong sensory organelle that protrudes from the surface of most mammalian cells. Within 
the cilium, BBS proteins are involved in a wide variety of processes ranging from regulation of intraflagellar 
transport to chaperonin and GTPase activity. On retinal disease information database, RetNet: Summaries of 
genes and loci causing retinal diseases, more than 20 genes are enlisted as causative of BBS. The BBS phenotype 
is multi-systemic, its primary features are blindness, renal dysfunction, intellectual disability, polydactyly, obesity 
and hypogonadism2. In addition, secondary characteristics include hepatic malfunction, type 2 diabetes mellitus, 
slow growth, psychomotor delay, delayed speech development, hearing loss and cardiac malformations. A BBS 
diagnosis can be made with the presence of at least four cardinal features, or a combination of three cardinal plus 
two secondary features2. BBS is mostly inherited as an autosomal recessive trait, but there have been a few reports 
that indicate oligogenic inheritance for BBS3–5, however, this mode of inheritance has been under discussion6–9.
BBS is a rare disorder with differences in the prevalence of the disease in different populations. For exam-
ple, among the total live births, in North America and Europe BBS affects 1 out of 140,000–160,00010,11, but 
BBS is more common in Newfoundland (1/17,000)12 as well as in Kuwaiti bedouins (1/13,500)13 and the Faroe 
Islands (1/3,700)14. These differences can be due to various factors including consanguinity, which is a social 
norm in countries such as Kuwait, Iran, Saudi Arabia and Pakistan. At the genomic level, about 10% of the total 
genome has been estimated to be homozygous in such families15. These homozygous regions generally contain 
the causative genetic mutation in recessive disorders such as BBS. The genetic defect is usually inherited from 
a single ancestor and is passed to the father and mother of the affected child who ultimately carries identical 
disease-causing (homozygous) mutations in both alleles of a gene16–18. In Pakistan more than 60% of the total 
marriages are consanguineous, and of these, about 80% are among first cousins16, which explains the high fre-
quency of homozygous mutations in families affected with recessive disorders.
The prevalence of BBS in Pakistan is not yet known. To date, there have been only nine reports of 18 Pakistani 
families with mutations in eight genes already known to be involved in BBS: ARL6 (OMIM #608845)19,20, BBS1 
(OMIM #209901)21, BBS2 (OMIM #606151), BBS5 (OMIM #603650)22, BBS9 (OMIM #615986)23, BBS10 (OMIM 
#610148)19,24,25, BBS12 (OMIM #610683)22,26 and TTC8 (OMIM #608132)27. Therefore, comprehensive studies are 
needed to further explore the genetic spectrum of BBS in the Pakistani population.
In this study, four families with classical BBS and one family with a BBS-like phenotype from Pakistan were 
genetically analyzed. In total, four homozygous mutations were identified, including mutations in ARL6 (F01), 
BBS5 (F02 and F03), BBS9 (F04) and CEP164 (F05). The identified mutations in ARL6 and BBS5 are novel.
Methods
Ethics statement. In the current study the recommendations of the Helsinki declaration were followed, and 
the “Ethics Review Board” of the COMSATS Institute of Information Technology, Islamabad and the contributing 
hospitals approved the study. The recruited families were informed in detail about the purpose of the study and 
their written consent was taken prior to blood sample collection and genetic analyses.
Selection and clinical evaluation of BBS families. A total of five families were included in this study, in 
which the diagnosis of BBS was made based on the criteria described by Beales et al.2, the phenotypes of these fam-
ilies are given in Table 1. Moreover, biochemical tests were performed that included urine (routine examination), 
serum creatinine and serum urea to evaluate renal function, gonadotropin levels were assessed to find indica-
tions of hypogonadism, and thyroid levels were analyzed to diagnose hypothyroidism (Supplementary Table S1). 
Abdominal and pelvic ultrasonography was also performed to assess anatomy of the vital organs, i.e. liver and 
kidneys. Cardiac function evaluation was done by electrocardiography (ECG). For the diagnosis of ocular abnor-
malities refraction testing, visual acuity testing and funduscopy were performed. Magnetic resonance imaging 
(MRI) for the assessment of brain anomalies were performed for one family (F05).
DNA isolation. Blood samples of the affected and healthy individuals of BBS families were collected in ethyl-
enediaminetetraacetic acid (EDTA) vacutainers. Genomic DNA was extracted from lymphocytes using a previ-
ously described standard protocol28 and then stored at − 20 °C until further use.
Targeted mutation screening. BBS probands were first screened for previously reported mutations occur-
ring in BBS-associated genes in Pakistani patients (Supplementary Table S2)29. The exons in which mutations 
have been reported previously, were amplified and analyzed by Sanger sequencing using dye-termination chem-
istry (BigDye Terminator, version 3 on a 3730 or 2100 DNA analyzer; Applied Biosystems, Foster City, CA).
Targeted exome sequencing (TES) of BBS genes. DNA of probands of whom no molecular diagnosis 
could be obtained after targeted mutation screening, were analyzed for mutations in 21 ciliopathy genes asso-
ciated with BBS using Fluidigm Technology (Supplementary Table S3). The targeted-exome sequencing (TES) 
analysis was performed on a next-generation sequencing MiSeq platform as previously reported30,31.
Whole exome sequencing and in silico predictions. The DNA of proband V:2 of BBS family F05 in 
whom no causative mutation was identified by TES was further analyzed by whole-exome sequencing (WES) 
using an Illumina HiSeq2000 platform. Genomic DNA from the proband was purified with a QIAamp DNA 
mini kit (cat# 51304) according to the manufacturer’s instructions. WES was performed at the Beijing Genomics 
Institute (BGI). The Agilent SureSelect version 4 exome kit was used for whole exome capture and a set of 
Illumina HiSeq 2 × 100 bp reads was generated. 72,192 reads were uniquely mapped to gene-coding regions and 
the exome had a median coverage of 50x. Variants were prioritized from WES data by using dbSNP (Feb 2009 
build, GRCh37/hg19) and an in-house SNP database consisting of 5,036 exomes. Variants were selected if they 
occurred at < 0.5% in the above-mentioned databases. The data were further prioritized by selecting truncating 
variants, splice site variation (until positions + 6/− 6) and missense variants with a Grantham score of ≥ 80 and/or 
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PhyloP ≥ 2.7 and/or PHRED scaled Combined Annotation–Dependent Depletion (CADD-PHRED) score 
> 15, which means that the variant is ranked among the top 5% of deleterious variations32. The cut-off values 
for the Grantham and PhyloP were based on a report of Vissers et al.33. The pathogenicity of variants was also 
assessed by various in silico programs including Polymorphism Phenotyping version 2 (Polyphen-2)34, Sorting 
Intolerant From Tolerant (SIFT)35 and Mutation Taster36. Supplementary Fig. S1 summarizes the filtering proto-
col. Homozygous regions in WES data were identified by using the homozygosity mapper37. CNV analysis was 
also performed on the WES data using the software Copy Number Inference From Exome Reads “CoNIFER 
version 0.2.2”38. WES reads with mapping quality (MAPQ) score >20 were prioritized and respective binary 
sequence alignment map (BAM) files were used for CNV detection.
Mutation segregation analysis. Prioritized variants were first confirmed by Sanger sequencing followed 
by segregation analysis in the respective families.
Splice site prediction. The ARL6 synonymous mutation (c.534A > G; p.(Q178Q)) was identified in family 
F01 by TES. The effect of this synonymous change on splicing was assessed in silico using Alamut visual Version 
2.7.1 from Interactive Biosoftware (http://www.interactive-biosoftware.com) (Supplementary Fig. S2).
Minigene splicing assay. The predicted effect of splice site mutation in ARL6 (c.534A > G; p.(Q178Q)) 
was validated by in vitro experiments using a minigene assay as previously described by Cooper39. The amplified 
DNA fragments of 656 bp carrying ARL6 exon 8 along with its flanking intronic sequences were cloned between 
RHO exon 3 and exon 5 in pCIneo mammalian expression vector. HEK293T cells in passage 20 were transfected 
using polyethylenimine (PEI) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
calf serum (FCS), 1% pyruvate and 1% antibiotic mixture of penicillin and streptomycin followed by 48 hours of 
incubation at 37 °C. Nucleospin kit (RNA-MACHEREY-NAGEL-05/2014, Rev 16) was used for total RNA isola-
tion, and iSCRIPT (BioRad) RT-PCR kit was used to perform reverse transcriptase (RT) PCR. Rhodopsin exon 
3 forward and exon 5 reverse primers (Supplementary Table S4) were used to detect the effect of the variant on 
splicing. The amplified fragments were electrophoretically separated on agarose gel followed by purification and 
Sanger sequencing (Fig. 1).
Family 
ID
Pedigree 
ID Diagnosis Gender
Age (yrs) at 
diagnosis BMI CRD/RP Polydactyly Obesity
Intellectual 
disability Hypogonadism Renal anomalies Additional features
F01
IV:2
BBS
M 32 ND Yes Yes ND No Yes
Renal 
parenchymal 
disease; deceased 
due to renal 
failure
NA
IV:3 M 40 ND Yes Yes ND No Yes No
Elevated liver enzymes, 
abnormal ECG, 
gynaecomastia
F02
IV:I
BBS
M 47 25.2 Yes Yes No Yes Yes Bilateral renal calculi
Hypodontia, syndactyly, 
brachydactyly, ataxia, speech 
disability, gall bladder 
calculi, mild spleno- and 
hepatomegaly, elevated liver 
enzymes, abnormally high 
cholesterol level
IV:2 M 45 25.1 Yes No No Yes Yes Bilateral renal calculi Speech disability
F03 IV:2 BBS F 15 26.6 Yes Yes No No Yes No
Developmental delay, 
irregular menstruation, 
low progesterone levels, 
diabetes, borderline 
hepatomegaly with fatty 
infiltration, abnormally high 
cholesterol level, elevated 
liver enzymes
F04 IV:2 BBS M 15 33.3 Yes Yes Yes Yes Yes
Left kidney: 
focal caliectasis 
in upper and 
interpolar region
Elevated liver enzymes, 
hypodontia, speech 
disability, gynaecomastia
F05
V:2
BBS-like
M 20 33.8 Yes No Yes Yes Yes No Gynaecomastia, cerebral atrophy
V:4 F 25 32.9 Yes No Yes ND Yes No
Irregular menstruation, 
Severe depression and 
psychosis at 26 yrs
Table 1.  Clinical features of affected individuals from BBS families. Abbreviations: BBS: Bardet Biedl 
syndrome, BMI: Body mass index, CRD: Cone-rod dystrophy, ECG: Electrocardiogram, ID: Identity, NA: Not 
applicable, ND: Not determined, RP: Retinitis pigmentosa, Yrs: Years. Also refer to Table S1.
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Results
Families F01, F02, F03 and F04 had classical BBS phenotypes, whereas family F05 was diagnosed as having 
BBS-like symptoms (Table 1).
Pre-screening of known mutations. None of the previously reported mutations in BBS1, BBS2, BBS5, 
BBS10, BBS12, ARL6 and TTC8 (Supplementary Table S2) in Pakistani BBS patients29, were found in the current 
panel and were therefore excluded as the causative factor in these families.
TES revealed mutations in ARL6, BBS5 and BBS9. The TES analysis of the 21 previously reported cili-
opathy genes associated with BBS (Supplementary Table S3) resulted in the identification of a novel synonymous 
variant c.534A > G; p.(Q178Q) in ARL6 in family F01, and a novel 11 bp deletion c.734_744del; p.(E245Gfs*18) 
in BBS5 in families F02 and F03 (Fig. 2). A recurrent mutation in BBS9, c.1789C > T; p.(Q597*)40, was identified 
in family F04 (Fig. 2; Table 2). All three variants segregated with the disease phenotype in the respective fam-
ilies, which means that the affected individuals in these families were homozygous for the detected mutations 
while their unaffected relatives were not. TES analysis revealed a heterozygous mutation in BBS12, (c.2014G > A; 
p.(A672T)) in family F05, which did not segregate in this family (Table 2), in addition no CNVs were detected, 
therefore family F05 was further analyzed by WES.
Functional validation of the ARL6 synonymous variant c.534A > G; p.(Q178Q). In silico analysis 
using splice prediction tools predicted that the synonymous change c.534A > G; p.(Q178Q) found in ARL6 in 
F01, could affect the normal splicing of exon 8 (Supplementary Fig. S2). The predicted effect on splicing of exon 8 
was validated with a minigene splice assay, which confirmed that the c.534A > G is a variant that causes skipping 
of exon 8 of ARL6 (Fig. 1). Exon skipping in turn results in a premature stop codon at residue 160 (p.(C160*)).
WES identified a CEP164 variant in family F05. The variants identified by WES analysis (Table 3) 
of family F05 were selected after in silico analyses, out of which the recurrent missense mutation c.277C > T; 
p.(R93W) in CEP16441 segregated with the disease phenotype in this family (Fig. 2; Supplementary Fig. S1; 
Table 3).
LOVD mutation updates. The identified variants in the respective families were not found in the con-
trol individuals. We have uploaded all the variants in the respective Leiden Open (source) Variation Databases 
(LOVDs), uploaded data are available at http://databases.lovd.nl/shared/genes/ARL6, http://databases.lovd.nl/
shared/genes/BBS5, http://databases.lovd.nl/shared/genes/BBS9 and http://databases.lovd.nl/shared/genes/
CEP164. As an alternate LOVD gene specific data can be viewed by typing www.lovd.nl/ followed by gene symbol.
Discussion
In the current study genetic characterization of five families from Pakistan are reported, four families had classic 
BBS and one family was diagnosed with a BBS-like syndrome. Two novel causative homozygous variants were 
Figure 1. Sequencing electropherograms of the minigene splicing assay constructs in family F01. The 
transcriptome analysis of transfected HEK293T cells revealed that in wild-type construct ARL6 exon 8 was 
retained in the transcript (upper panel) whereas in mutant construct ARL6 exon 8 skipped splicing and was 
absent in the transcript (lower panel). Thus, this synonymous mutation indeed results in aberrant splicing in 
family F01.
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identified in ARL6 and BBS5 in three families F01, F02 and F03, and previously reported variants were detected 
in BBS9 and CEP164 in the remaining two families F04 and F05, respectively.
In family F01, a novel synonymous variant c.534A > G; p.(Q178Q) was identified in exon 8 of ARL6. Although 
this variant does not affect the glutamine codon, in silico analysis predicted this mutation to result in aberrant 
splicing (Supplementary Fig. S2). As adenine at position 534 is the second last nucleotide in exon 8, and is located 
in the consensus splice site sequence, the transition of this adenine to a guanine will likely result in exon-skipping 
during splicing. Result of an in vitro splicing assay confirmed the generation of mutated mRNA and provides 
support for the pathogenic nature of this novel variant. Exon 8 of ARL6 indeed appeared to be skipped during 
the splicing process, which results in a frameshift that causes a premature stop codon at position 160 (p.(C160*)) 
that may lead to the production of a truncated ARL6 peptide. However, aberrantly spliced mRNAs containing 
premature stop codons are usually degraded in a process that is known as nonsense mediated decay (NMD)42,43. 
However, when analyzing the phenotypes of the affected siblings in F01 (IV:2 and IV:3) having the common 
genetic defect, it is obvious that besides clinical overlap there are also clinical differences between the siblings. For 
example, proband (IV:3) had no renal disease, whereas his affected brother (IV:2) died because of renal failure 
at the age of 35 (Table 1). In addition, the degree of polydactyly varies between the siblings, i.e. while IV:2 had 
postaxial hexadactyly of both hands and feet, IV:3 only displayed hexadactyly of both feet.
In families F02 and F03, a novel frameshift mutation c.734_744del; p.(E245Gfs*18) was found in exon 9 of 
BBS5. The frameshift probably creates a null allele since the mRNA is likely to be degraded by NMD. In case of the 
synthesis of a truncated BBS5 protein, 78 amino acid residues from the C-terminus will be missing, which might 
affect BBSome assembly44,45 that in turn is likely to disturb normal ciliary transport mechanisms. Both families 
(F02 and F03) originate from the same region in Pakistan and we hypothesized that these families may be related 
to each other. However, both families had no information on their possible relationship. Despite having the same 
Figure 2. Pedigrees showing identified mutations segregating in BBS families. Squares and circles represent 
males and females, respectively. Unfilled symbols indicate healthy individuals and filled symbols indicate 
affected individuals, symbols with a diagonal line represent deceased individuals. ‘M’ represents the mutant 
allele and ‘+ ’ represents ancestral allele. Arrow in pedigree F05 indicates the individual analyzed by WES.
Family Id Gene Allele 1 Allele 2 Protein variant
ExAC allele 
frequency (Total) SIFT (score) Polyphen V2 Taster (p-value)
F01 ARL6 c.534A > G c.534A > G p = p.(Q178Q) 1/121,316 NA NA NA
F02 BBS5 c.734_744del c.734_744del p.(E245Gfs*18) 0 NA NA NA
F03 BBS5 c.734_744del c.734_744del p.(E245Gfs*18) 0 NA NA NA
F04 BBS9 c.1789C > T c.1789C > T p.(Q597*) 0 NA NA NA
F05 BBS12 c.2014G > A + p.(A672T) 149/119,520 Del (0.0) DC (1.0) PrD (1.000)
Table 2.  Genetic variations identified by targeted exome sequencing of 21 BBS-associated genes in 
Pakistani BBS families. Abbreviations: DC: Disease causing, Del: deleterious, PrD: Probably damaging, ExAC: 
Exome aggregation consortium, SIFT: Sorting intolerant from tolerant, NA: Not applicable, Polyphen V2: 
Polymorphism phenotyping version2. In case of protein truncating mutations these values are not applicable.
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mutation, phenotypic variability was apparent within and between both families. Within family F02, proband 
(IV:1) has post axial hexadactyly on left foot, syndactyly of middle and ring finger on left hand and brachydactyly 
of both feet, whereas his affected sibling (IV:2) did not (Table 1). With respect to the clinical variation between 
families, it is apparent that the affected female in F03 did not have intellectual disability or renal anomalies, 
while these features were reported in both affected individuals of family F02 (Table 1). In addition, Table 1 shows 
various other phenotypic differences between families and patients. As observed for F01, phenotypic variability 
within and between F02 and F03 may be attributed to yet unknown modifying factors21,46. Generally, the exist-
ence of modifier alleles imposes a great challenge in establishing clear-cut genotype-phenotype correlations and 
complicates an accurate prognosis for affected individuals.
In family F04 a previously reported nonsense mutation c.1789C > T; p.(Q597*) was identified in BBS9 by TES. 
This mutation had previously been reported in a homozygous state as the primary cause of a form of hereditary 
blindness known as retinitis pigmentosa (RP) in a Latino proband40. Other criteria for BBS in the Latino proband 
were not determined while the current proband IV:2 from family F04 was fully characterized and diagnosed with 
BBS (Table 1). With incomplete data of the Latino proband, the phenotypes cannot be compared between the 
current and the previous study. At the molecular level, as a result of this mutation, BBS9 transcripts in this family 
(F04) are likely to be degraded by NMD. Alternatively, synthesis of a truncated protein may lead to disrupted 
BBSome assembly47, ciliary biogenesis and function48.
Based on results from previous studies and our current study, eight out of the 21 BBS-associated genes have 
been found mutated in Pakistani patients with BBS features (Supplementary Fig. S3). Thus far, 44 patients from 22 
BBS-families19–27,49, including four BBS families from the current study, have been identified in Pakistan. In this 
group, BBS10 mutations were most common and were identified in 27% of the cases, and mutations in BBS5 were 
the second most common and explained 18% of the reported BBS families (Supplementary Fig. S3).
This analysis does not include the BBS-like family F05 from the present study. Affected individuals in family 
F05 were initially suspected of BBS based on the co-occurrence of RP, obesity, intellectual disability and hypo-
gonadism in this family (Table 1). As F05 is a consanguineous family, homozygosity mapping was performed 
on the WES data, which revealed the presence of candidate gene CEP164 in the fourth-largest homozygous 
region of 16 Mb (Supplementary Table S5). This was an interesting observation as this gene had previously been 
associated with Nephronophthisis (NPHP) 15 [OMIM: #614845] that is characterized by various ciliopathy fea-
tures41. WES analysis of proband V:2 indeed identified a homozygous missense mutation c.277C > T; p.(R93W) 
in CEP164 in family F05. Although structural information of the CEP164 protein remains absent to date, the 
affected amino acid is just downstream of the predicted WW domain of the protein (aa 57-89) that is known 
to mediate protein-protein interactions and might affect its structure50. The p.(R93W) variant had previously 
been reported in a compound heterozygous state together with a truncating mutation c.1573C > T; p.(Q525*) on 
the second allele in a family with three affected individuals of whom two presented with NPHP and blindness, 
while the third patient also had mild intellectual disability41. The F05 probands also had neural defects; V:2 had 
mild cerebral atrophy. In addition, psychological problem was observed in V:4 who developed obsessive com-
pulsive disorder and psychosis at the age of 26 years. Remarkably, while all but one family with CEP164 defects 
(c.277C > T; p.(R93W) and other mutations) reported by Chaki et al.41 had renal insufficiency during childhood; 
the affected individuals in F05 did not have any sign of renal anomalies at 21 and 26 years of age (Table 1), respec-
tively. A single patient without renal insufficiency reported by Chaki et al.41 was described as a nonsyndromic RD 
(LCA) patient, a mild phenotype compared with the syndromic features of other patients carrying mutations in 
CEP164 and likely caused by the specific missense mutation of the CEP164 stop codon in this patient. Family F05 
in our study was thus diagnosed with BBS-like syndrome instead of NPHP15 or BBS. It is interesting to note that 
Chaki et al.41, also reported a patient with a homozygous p.(R576*) mutation who showed a broader syndromic 
phenotype that included cerebellar vermis hypoplasia, bilateral polydactyly, abnormal liver function and obesity. 
In conclusion, our results confirm that mutations in CEP164 can result in a broadly variable clinical outcome 
between and within families, varying from non-syndromic retinal degeneration to a BBS-like phenotype, which 
implies that there are restrictions on making an accurate diagnosis and prognosis in these families. Molecularly, 
the phenotypic resemblance with BBS is in line with the shared direct molecular association of both CEP164 and 
the BBSome with Rabin8, which mediates membrane assembly of the primary cilia50,51.
Conclusion
Our data confirm inter-/intra-familial clinical heterogeneity in patients having common genetic defects in BBS 
genes, and describe a broader clinical phenotypic spectrum resulting from mutations in CEP164, extending 
it beyond retinal-renal ciliopathies to a BBS-like phenotype. Further studies are needed to establish if certain 
Chr Gene Variation Zygosity Depth
ExAc frequency 
Total phyloP
CADD_
PHRED
Grantham 
Score SIFT (score) Polyphen V2
Mutation taster 
(p-value)
11 CEP164 c.277C > T; p.(R93W) Hom 34 1/121,408 4.165 29 101 Del (0.0) PrD (1.000) DC (1.0)
4 BBS12 c.2014G > A; p.(A672T) Het 115 149/119,520 5.869 34 58 Del (0.0) PrD (1.000) DC (1.0)
Table 3.  Filtered variants after WES analysis in family F05. Abbreviations: CADD: Combined Annotation 
Dependent Depletion, Chr: Chromosome, DC: Disease causing, Del: Deleterious, ExAC: Exome aggregation 
consortium, Het: Heterozygous, Hom: Homozygous, PhyloP: Phylogenetic p-value, Polyphen V2: 
Polymorphism phenotyping version2, PrD: Probably damaging, SIFT: Sorting intolerant from tolerant.
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phenotypic features are associated with dysfunction of specific BBS genes, and if phenotypic differences between 
and within families can be explained by genetic modifiers. These molecular insights are helpful in genetic coun-
seling of the affected families to prevent disease inheritance in the next generations.
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